论文部分内容阅读
比索洛尔是普奈洛尔和美托洛尔之后的新一代高选择性β1肾上腺素能受体阻滞剂。2006年1月至2009年10月我院在常规抗心衰治疗基础上加用比索洛尔,取得满意疗效,报告如下。1资料与方法1.1临床资料2006年1月至2009年10月收治扩张型心肌病全心衰患者64例,均经病史,体检,胸片及超声心动图确诊。治疗组32例,男20例,女12例,年龄52～78岁,平均
Bisoprolol is a new generation of highly selective beta 1 adrenergic receptor blockers after propranolol and metoprolol. January 2006 to October 2009 our hospital in the conventional anti-heart failure treatment based on the addition of bisoprolol, and achieved satisfactory results, the report is as follows. 1 Materials and Methods 1.1 Clinical data January 2006 to October 2009 admitted to patients with heart failure of dilated cardiomyopathy 64 cases were diagnosed by history, physical examination, chest X-ray and echocardiography. Treatment group of 32 patients, 20 males and 12 females, aged 52 to 78 years, mean